Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD3/anti-BCMA bispecific antibody TQB2934

A T-cell engaging, human, bispecific, immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD3/anti-BCMA bispecific antibody TQB2934 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-BCMA/anti-CD3 bispecific antibody TQB2934
anti-CD3 x BCMA double-specific antibody TQB2934
anti-CD3/anti-BCMA T-cell engaging bispecific antibody TQB2934
anti-CD3/BCMA bispecific antibody TQB2934
bispecific antibody TQB2934
Code name:TQB 2934
TQB-2934
TQB2934
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search